What is the 13F Pro Quality Score for DCTH?

13F Pro ranks DELCATH SYSTEMS, INC. (DCTH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DCTH's current score at https://13fpro.ai/research/DCTH (free sign-up required for the full ranking).

Which hedge funds own the most DCTH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DCTH include Rosalind Advisors,, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/DCTH as soon as new 13F filings post.

Where does 13F Pro source DCTH data?

All DELCATH SYSTEMS, INC. fundamentals and ownership data come directly from SEC EDGAR. DELCATH SYSTEMS, INC. files with the SEC under CIK 872912. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DCTH in?

DELCATH SYSTEMS, INC. (DCTH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DCTH research updated on 13F Pro?

DCTH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DELCATH SYSTEMS, INC.(DCTH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 872912 DCTH stock profile & AI dashboard →

13F Pro Quality Score

54.9/100

Rank #1,188 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

96.7/100

Profitability

50.9/100

Balance Sheet

57.0/100

Earnings Quality

30.0/100

Free Cash Flow

72.8/100

Institutional Flow

32.5/100

Revenue Scale

16.3/100

Dilution Risk

6.7/100

DCTH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for DELCATH SYSTEMS, INC. (DCTH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DCTH at 54.9/100 on a 32-signal composite quality model, placing it at rank #1,188 of 2,879 stocks — the top half of the AI-ranked universe. DCTH scores in the top quartile across revenue growth (96.7). Areas of concern include revenue scale (16.3) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), DELCATH SYSTEMS, INC. reports quarterly revenue of $25.0M, net income of $-1.1M, an operating margin of -6.6%. Top institutional holders of DCTH by reported 13-F value include Rosalind Advisors,, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. DCTH trades on the Nasdaq exchange and files with the SEC under CIK 872912. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DCTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DELCATH SYSTEMS, INC. directly from SEC EDGAR. DELCATH SYSTEMS, INC.'s 13F Pro composite quality score has ranged between 28 and 62 since 2025, currently 54.9 — an improving long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about DELCATH SYSTEMS, INC.

Quirks, history, and lore behind DCTH — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. medical device company · listed on Nasdaq · focused on oncology treatments.
2
The Numbers
Revenue in the low single-digit millions annually — this is a commercial-stage company still working hard to scale its niche technology.
3
The History
The company spent decades in development pursuing regulatory approval, finally earning a CE Mark in Europe before gaining a foothold in the U.S. market.
4
The Secret
Its flagship system works by isolating the liver from the body's general circulation, flooding it with a high dose of chemotherapy that would be toxic if delivered systemically.
5
The Lore
The procedure it enables — percutaneous hepatic perfusion — is designed for patients with metastatic liver cancer who have few other options, making it a genuine last-resort tool.
6
The Giveaway
Its HEPZATO KIT (melphalan for injection) received FDA approval in 2023 for ocular melanoma that has spread to the liver — a disease so rare most oncologists never see a case.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$25.0M

Net Income

Q1 2026

$-1.1M

Free Cash Flow

Q1 2026

$287.0K

Operating Margin

Q1 2026

-6.6%

ROIC

Q1 2026

-1.5%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+129.1% YoY

$85.2MFY 2025

FY22 $2.7MFY23 $2.1MFY24 $37.2MFY25 $85.2M

Net Income

+110.2% YoY

$2.7MFY 2025

FY22 $-36.5MFY23 $-47.7MFY24 $-26.4MFY25 $2.7M

Operating Income

+105.3% YoY

$660.0KFY 2025

FY22 $-33.9MFY23 $-38.2MFY24 $-12.4MFY25 $660.0K

EPS (Diluted)

+107.5% YoY

$0.07FY 2025

FY22 $-4.12FY23 $-2.94FY24 $-0.93FY25 $0.07

Total Assets

+61.4% YoY

$123.6MFY 2025

FY22 $17.9MFY23 $38.6MFY24 $76.6MFY25 $123.6M

Total Debt

—FY 2025

FY22 $15.7MFY23 $10.2MFY24 $0.00FY25 —

Op. Cash Flow

+220.5% YoY

$22.5MFY 2025

FY22 $-24.9MFY23 $-31.3MFY24 $-18.7MFY25 $22.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$85.2M +129.1%	$37.2M +1701.7%	$2.1M -24.1%	$2.7M -23.5%	$3.6M	—
Net Income	$2.7M +110.2%	$-26.4M +44.7%	$-47.7M -30.6%	$-36.5M -42.3%	$-25.6M -6.2%	$-24.2M
Operating Income	$660.0K +105.3%	$-12.4M +67.5%	$-38.2M -12.8%	$-33.9M -38.0%	$-24.5M -15.2%	$-21.3M
EPS (Diluted)	$0.07 +107.5%	$-0.93 +68.4%	$-2.94 +28.6%	$-4.12 -14.8%	$-3.59 +57.0%	$-8.35
Total Assets	$123.6M +61.4%	$76.6M +98.4%	$38.6M +116.2%	$17.9M -46.1%	$33.1M -4.4%	$34.6M
Total Debt	—	$0.00 -100.0%	$10.2M -35.3%	$15.7M	—	—
Operating Cash Flow	$22.5M +220.5%	$-18.7M +40.2%	$-31.3M -25.3%	$-24.9M -10.4%	$-22.6M +1.2%	$-22.9M

AI Insight: DCTH Financial Trends

Revenue tripled from $8M to $25M in six quarters, but operating losses have re-emerged in the most recent two periods despite that top-line momentum.

• Revenue surged from $8M in Q2 2024 to $25M in Q1 2026, a ~3x increase over six quarters.

• Operating cash flow turned positive in Q1 2025 ($2M) and peaked at $8M in Q4 2025, a meaningful improvement from persistent negatives in 2024.

• Total debt was eliminated by Q4 2024 (from $4M in Q2 2024), while equity expanded from $4M to $113M in Q1 2026.

• Operating income turned negative again in Q3 2025 (-$0M) and Q4 2025 (-$2M), persisting into Q1 2026 (-$2M) after profitable Q1–Q2 2025.

⚠ Operating income has been negative three consecutive quarters through Q1 2026 — monitor whether rising costs are outpacing revenue growth.

⚠ Revenue dipped from $24M in Q2 2025 to $21M in Q3–Q4 2025 before recovering to $25M — watch for sustained sequential growth resumption.

⚠ Operating CF dropped sharply to $1M in Q1 2026 from $8M in Q4 2025 — a potential early stress signal worth tracking.

AI Insight: DCTH Ratio Trends

DCTH's profitability has reversed sharply after a mid-2025 peak, with operating margin falling from 10.7% in Q2 2025 to -6.6% in Q1 2026.

• Operating margin peaked at 10.7% in Q2 2025 but deteriorated to -10.5% in Q4 2025 and -6.6% in Q1 2026.

• ROIC turned negative in Q3 2025 at -1.4%, worsened to -7.8% in Q4 2025, and remained negative at -5.8% in Q1 2026.

• TTM net profit margin is barely positive at 0.6%, masking three consecutive quarterly net losses through Q1 2026.

⚠ Four consecutive quarters of margin deterioration since Q2 2025 peak — watch whether Q2 2026 signals stabilization or continued decline.

⚠ D/E data is absent from Q1 2025 onward; leverage trajectory is unverifiable and warrants direct balance-sheet scrutiny.

⚠ ROA dropped from 9.2% in Q2 2025 to -3.4% in Q1 2026 — asset productivity eroding rapidly over three quarters.

Get alerted when DCTH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DELCATH SYSTEMS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DCTH

Rosalind Advisors, Inc.
$30.6M3,300,389 sh
BlackRock, Inc.
$16.6M1,784,466 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.3M1,329,288 sh
Propel Bio Management, LLC
$9.2M979,698 sh
GEODE CAPITAL MANAGEMENT, LLC
$6.4M692,031 sh
STATE STREET CORP
$6.2M664,428 sh
Private Wealth Advisors, LLC
$5.5M591,524 sh
MILLENNIUM MANAGEMENT LLC
$5.5M588,055 sh
Divisadero Street Capital Management, LP
$4.6M499,796 sh
Ikarian Capital, LLC
$4.0M431,251 sh

Fund	Value	Shares
Rosalind Advisors, Inc.	$30.6M	3,300,389
BlackRock, Inc.	$16.6M	1,784,466
VANGUARD CAPITAL MANAGEMENT LLC	$12.3M	1,329,288
Propel Bio Management, LLC	$9.2M	979,698
GEODE CAPITAL MANAGEMENT, LLC	$6.4M	692,031
STATE STREET CORP	$6.2M	664,428
Private Wealth Advisors, LLC	$5.5M	591,524
MILLENNIUM MANAGEMENT LLC	$5.5M	588,055
Divisadero Street Capital Management, LP	$4.6M	499,796
Ikarian Capital, LLC	$4.0M	431,251

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DCTH on your watchlist

Track score changes the day DELCATH SYSTEMS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DCTH a good stock to buy?

13F Pro's AI-powered analysis of DELCATH SYSTEMS, INC. (DCTH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DCTH are available on the DCTH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DCTH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DCTH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DELCATH SYSTEMS, INC.'s investment landscape.